Literature DB >> 22632094

Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.

Amy Hauck Newman1, Thijs Beuming, Ashwini K Banala, Prashant Donthamsetti, Katherine Pongetti, Alex LaBounty, Benjamin Levy, Jianjing Cao, Mayako Michino, Robert R Luedtke, Jonathan A Javitch, Lei Shi.   

Abstract

The <span class="Chemical">dopamine D3 receptor (<span class="Chemical">D3R) has been implicated in substance abuse and other neuropsychiatric disorders. The high sequence homology between the D3R and D2R, especially within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compounds challenging. Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compounds and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy. We find that selectivity arises from divergent interactions within a second binding pocket (SBP) separate from the OBS, whereas efficacy depends on the binding mode in the OBS. Our findings reveal structural features of the receptor that are critical to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies. These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632094      PMCID: PMC3415572          DOI: 10.1021/jm300482h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  42 in total

1.  Real-time monitoring of receptor and G-protein interactions in living cells.

Authors:  Céline Galés; R Victor Rebois; Mireille Hogue; Phan Trieu; Andreas Breit; Terence E Hébert; Michel Bouvier
Journal:  Nat Methods       Date:  2005-02-17       Impact factor: 28.547

2.  Role of the active-site solvent in the thermodynamics of factor Xa ligand binding.

Authors:  Robert Abel; Tom Young; Ramy Farid; Bruce J Berne; Richard A Friesner
Journal:  J Am Chem Soc       Date:  2008-02-12       Impact factor: 15.419

3.  High-energy water sites determine peptide binding affinity and specificity of PDZ domains.

Authors:  Thijs Beuming; Ramy Farid; Woody Sherman
Journal:  Protein Sci       Date:  2009-08       Impact factor: 6.725

Review 4.  Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.

Authors:  Fabrizio Micheli
Journal:  ChemMedChem       Date:  2011-03-18       Impact factor: 3.466

Review 5.  The D3 dopamine receptor: neurobiology and potential clinical relevance.

Authors:  B Levant
Journal:  Pharmacol Rev       Date:  1997-09       Impact factor: 25.468

Review 6.  Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates.

Authors:  Stefan Löber; Harald Hübner; Nuska Tschammer; Peter Gmeiner
Journal:  Trends Pharmacol Sci       Date:  2011-01-12       Impact factor: 14.819

Review 7.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

8.  The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor.

Authors:  G Liapakis; J A Ballesteros; S Papachristou; W C Chan; X Chen; J A Javitch
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

9.  A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.

Authors:  Tod Steinfeld; Mathai Mammen; Jacqueline A M Smith; Richard D Wilson; Jeffrey R Jasper
Journal:  Mol Pharmacol       Date:  2007-05-03       Impact factor: 4.436

10.  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.

Authors:  Amy Hauck Newman; Peter Grundt; George Cyriac; Jeffrey R Deschamps; Michelle Taylor; Rakesh Kumar; David Ho; Robert R Luedtke
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

View more
  60 in total

1.  Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.

Authors:  J Robert Lane; Pavel Chubukov; Wei Liu; Meritxell Canals; Vadim Cherezov; Ruben Abagyan; Raymond C Stevens; Vsevolod Katritch
Journal:  Mol Pharmacol       Date:  2013-09-10       Impact factor: 4.436

2.  Regional Heterogeneity of D2-Receptor Signaling in the Dorsal Striatum and Nucleus Accumbens.

Authors:  Pamela F Marcott; Sheng Gong; Prashant Donthamsetti; Steven G Grinnell; Melissa N Nelson; Amy H Newman; Lutz Birnbaumer; Kirill A Martemyanov; Jonathan A Javitch; Christopher P Ford
Journal:  Neuron       Date:  2018-04-12       Impact factor: 17.173

3.  Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor.

Authors:  R Benjamin Free; Lani S Chun; Amy E Moritz; Brittney N Miller; Trevor B Doyle; Jennie L Conroy; Adrian Padron; Julie A Meade; Jingbo Xiao; Xin Hu; Andrés E Dulcey; Yang Han; Lihua Duan; Steve Titus; Melanie Bryant-Genevier; Elena Barnaeva; Marc Ferrer; Jonathan A Javitch; Thijs Beuming; Lei Shi; Noel T Southall; Juan J Marugan; David R Sibley
Journal:  Mol Pharmacol       Date:  2014-04-22       Impact factor: 4.436

Review 4.  What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?

Authors:  Mayako Michino; Thijs Beuming; Prashant Donthamsetti; Amy Hauck Newman; Jonathan A Javitch; Lei Shi
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

5.  Mutation of three residues in the third intracellular loop of the dopamine D2 receptor creates an internalization-defective receptor.

Authors:  Cecilea C Clayton; Prashant Donthamsetti; Nevin A Lambert; Jonathan A Javitch; Kim A Neve
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

Review 6.  Dopamine receptors - IUPHAR Review 13.

Authors:  Jean-Martin Beaulieu; Stefano Espinoza; Raul R Gainetdinov
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

7.  Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).

Authors:  Vivek Kumar; Amy E Moritz; Thomas M Keck; Alessandro Bonifazi; Michael P Ellenberger; Christopher D Sibley; R Benjamin Free; Lei Shi; J Robert Lane; David R Sibley; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-02-10       Impact factor: 7.446

Review 8.  Molecular Dynamics Simulation for All.

Authors:  Scott A Hollingsworth; Ron O Dror
Journal:  Neuron       Date:  2018-09-19       Impact factor: 17.173

9.  Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.

Authors:  Claudia Rangel-Barajas; Maninder Malik; Michelle Taylor; Kim A Neve; Robert H Mach; Robert R Luedtke
Journal:  J Neurochem       Date:  2014-08-19       Impact factor: 5.372

10.  Multiple fragment docking and linking in primary and secondary pockets of dopamine receptors.

Authors:  Márton Vass; Eva Agai-Csongor; Ferenc Horti; György M Keserű
Journal:  ACS Med Chem Lett       Date:  2014-07-10       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.